MICHAEL LARDON: Open Payments
NPI 1174630305 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,529 in 229 payments from 15 companies in 2025. Trend: 2023 $2,448 · 2024 $2,422 · 2025 $4,529
Food & beverage: $4,306Education: $223
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $736 |
| Neurocrine BioSciences, Inc. | 23 | $679 |
| Alkermes, Inc. | 30 | $543 |
| Teva Pharmaceuticals USA, Inc. | 16 | $521 |
| Otsuka America Pharmaceutical, Inc. | 31 | $396 |
| E.R. Squibb & Sons, L.L.C. | 24 | $364 |
| Vanda Pharmaceuticals Inc. | 23 | $243 |
| Axsome Therapeutics, Inc. | 10 | $229 |
| Bausch Health US, LLC | 13 | $203 |
| ABBVIE INC. | 11 | $193 |
Products named: CAPLYTA, INGREZZA, ARISTADA, COBENFY, FANAPT, Auvelity, UZEDY, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
